In this interview, Technology Networks spoke with Dr. Sophie Mayle, Dr. Paul Royle and Dr. John Cardone from Bio-Rad's ...

Hummingbird Bioscience, a precision biotherapeutics company discovering and developing transformative biologics for hard-to-treat diseases, today announced it has granted Immunome, Inc. (Nasdaq: IMNM) ...

PathAI, a leading provider of AI-powered technology for pathology, today announced a strategic partnership with Discovery Life Sciences, a leading biospecimens and specialty lab testing company, to ...

and BRUSSELS, Jan. 9, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, and XtalPi, a global leader in AI drug ... the entire antibody discovery and optimisation workflow," said ...

ultimately advancing the discovery and development of therapies and diagnostics that improve patient outcomes.” As investments in immuno-oncology and antibody-drug conjugates continue to rise ...

Learn more about whether Twist Bioscience Corporation or Veracyte, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

BioArctic AB (publ) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's Supplemental Biologics License Application (sBLA) for Leqembi as a once ...

Learn more about whether Legend Biotech Corporation or Twist Bioscience Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

ABS-101 appears to be ABSI’s main drug candidate ... so I would say its discovery process is highly optimized already. Also, note that ABSI uses De Novo Antibody Models that generate antibodies ...